Aryl sulfones: a new class of gamma-secretase inhibitors.
The development of a novel series of 4-aryl, 4-phenylsulfonyl cyclohexananone-derived gamma-secretase inhibitors for the potential treatment of Alzheimer's disease is described.
Teall
Martin
M
Department of Medicinal Chemistry, Merck Sharp & Dohme Research Laboratories, The Neuroscience Research Centre, Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR, UK. martin_teall@merck.com
Oakley
Paul
P
Harrison
Timothy
T
Shaw
Duncan
D
Kay
Euan
E
Elliott
Jason
J
Gerhard
Ute
U
Castro
José L
JL
Shearman
Mark
M
Ball
Richard G
RG
Tsou
Nancy N
NN
D000544:Alzheimer Disease / Q000188:drug therapy; D053829:Amyloid Precursor Protein Secretases; D016282:Aspartic Acid Endopeptidases / Q000037:antagonists & inhibitors*; D010450:Endopeptidases; D004791:Enzyme Inhibitors / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D008958:Models, Molecular; D013450:Sulfones / Q000737:chemistry / Q000494:pharmacology*
D004791:Enzyme Inhibitors; D013450:Sulfones; D053829:Amyloid Precursor Protein Secretases; D010450:Endopeptidases; D016282:Aspartic Acid Endopeptidases; C509280:BACE1 protein, human